肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

huMNC2-CAR44 T细胞疗法治疗转移性乳腺癌

2019-06-25 Allan MedSci原创

huMNC2-CAR44T细胞疗法转移性乳腺癌MUC1
关注

Minerva Biotechnologies是一家生物制药公司，专注于开发癌症免疫疗法，近日宣布，美国FDA已批准huMNC2-CAR44 T细胞疗法的研究性新药申请（IND）。

Minerva Biotechnologies是一家生物制药公司，专注于开发癌症免疫疗法，近日宣布，美国FDA已批准huMNC2-CAR44 T细胞疗法的研究性新药申请（IND）。huMNC2-CAR44 T细胞疗法能够靶向切割形式的MUC1（存在于超过75％的实体瘤癌细胞中）。与正常的全长MUC1不同，切割形式的MUC1是有效的生长因子受体，当肿瘤生长因子NME7AB与切割形式的MUC1的细胞外结构域结合并二聚化时，该受体具有组成型活性。Minerva打算在2019年底之前开始乳腺癌的临床试验。


原始出处：

http://www.firstwordpharma.com/node/1649108#axzz5rpYDX3hI

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1722983, encodeId=465c1e2298307, content=<a href='/topic/show?id=d6fb120491e' target=_blank style='color:#2F92EE;'>#MNC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12049, encryptionId=d6fb120491e, topicName=MNC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3833348890, createdName=lifangping, createdTime=Wed Oct 02 13:35:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386512, encodeId=50bf1386512cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478017, encodeId=733f14e8017d9, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-10-02 lifangping

    #MNC#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1722983, encodeId=465c1e2298307, content=<a href='/topic/show?id=d6fb120491e' target=_blank style='color:#2F92EE;'>#MNC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12049, encryptionId=d6fb120491e, topicName=MNC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3833348890, createdName=lifangping, createdTime=Wed Oct 02 13:35:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386512, encodeId=50bf1386512cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478017, encodeId=733f14e8017d9, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-06-27 1249842em09(暂无昵称)

    #转移性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1722983, encodeId=465c1e2298307, content=<a href='/topic/show?id=d6fb120491e' target=_blank style='color:#2F92EE;'>#MNC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12049, encryptionId=d6fb120491e, topicName=MNC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e3833348890, createdName=lifangping, createdTime=Wed Oct 02 13:35:00 CST 2019, time=2019-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386512, encodeId=50bf1386512cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478017, encodeId=733f14e8017d9, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18030, encryptionId=bb6f18030a4, topicName=T细胞疗法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6bea7392214, createdName=124984edm24暂无昵称, createdTime=Thu Jun 27 07:35:00 CST 2019, time=2019-06-27, status=1, ipAttribution=)]
    2019-06-27 124984edm24暂无昵称

    #T细胞疗法#

    0